ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0656

Association Study Identified HLA-DQA1 as a Genetic Risk of Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension

Junyan Qian1, Ying Chen2, Xinzhuang Yang3, Qian Wang4, JIULIANG ZHAO5, Xiaoyue Deng1, Shengjie Li3, Yongtai Liu6, Zhuang Tian6, Juan Shen2, Qijun Liao2, Yanhong Wang7, Xianbo Zuo8, Xuejun Zhang9, MENGTAO LI1, Yong Cui8, Xueqing Yu10 and Xiaofeng Zeng11, 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, 2BGI-Shenzhen, Shenzhen, China, 3Medical Research Center, State Key laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 4Peking Union Medical College Hospital, Beijing, China, 5Beijing Union Medical College Hospital, Beijing, China, 6Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, 7Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, China Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 8Department of Dermatology, China-Japan Friendship Hospital, Beijing, China, 9Institute of Dermatology, Anhui Medical University, Hefei, China, 10Division of Nephrology, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, 11Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

Meeting: ACR Convergence 2022

Keywords: Biomarkers, genetics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Pulmonary arterial hypertension (PAH) is a rare and severe complication of systemic lupus erythematosus (SLE). Human leucocyte antigen (HLA) gene variants in the major histocompatibility complex (MHC) region play key roles in the pathogenesis of SLE. However, the genetic characteristics of HLA in SLE-associated PAH has not been established. In this study, we aimed to identify genetic variants implicated with SLE-associated PAH susceptibility within the MHC region and assessed the contribution of associated variants to clinical outcomes.

Methods: A total of 172 patients with SLE-associated PAH confirmed by right heart catheterization, 1,303 cases of SLE without PAH and 9,906 healthy controls were included. Deep sequencing was performed on the entire 5-Mb MHC region to identify HLA alleles, single nucleotide polymorphism (SNPs) and amino acid. To determine the HLA genetic variants specifically associated with SLE-associated PAH, we compared it with two groups of controls, which were SLE without PAH (SLE-nonPAH) and healthy controls. Functional analysis were then performed for significant associated SNPs by exploring the evidence of colocalization with expression quantitative trait loci (eQTLs). Finally, we conducted the clinical association study in SLE-associated PAH patients with the significant associated HLA allele.

Results: 19,881 variants were identified, including SNPs, alleles, and amino acid within the MHC region. HLA-DQA1*03:02 was observed presenting the most significant association for SLE-associated PAH when comparing with both healthy controls and SLE-nonPAH. The top significant associated amino acid was mapped to HLA-DQα1 in the region affecting MHC/peptide-CD4+ T cell receptor affinity and antigen binding. Five SNPs were independent detected significantly associated with SLE-associated PAH. Colocalization analysis revealed rs2395310 in HLA-DOA/DPA1 affects the gene expression of HLA-DPA1 and HLA-DPB2 in heart, artery and lung. Clinical association study showed SLE-associated PAH patients with HLA-DQA1*03:02 had worse target role achievement (TGA) and survival rate compared to patients without it.

Conclusion: This is the first study investigating the genetic variants that contribute to SLE-associated PAH susceptibility of the MHC region. HLA-DQA1*03:02 is considered to be a genetic risk factor for the further development of PAH in SLE patients. This HLA allele was also associated with worse clinical outcomes in patients with SLE-associated PAH. SLE patients with this allele type require regular and careful follow-up for early diagnosis and interventions for possible PAH.

Supporting image 1

Figure 1. Study flow-chart. HLA=human leukocyte antigen; BWA=Burrows-Wheeler Alignment Tool; GATK=Genome Analysis Toolkit.

Supporting image 2

Figure 2. Association analysis for SLE-associated PAH within MHC regions. The -log10 of P values are plotted against their chromosomal position. The dotted line represents the level of statistical significance (P value=2.5×10−6). Colored signals represent alleles (dark blue), amino acids (light blue) and SNPs (grey) associated with SLE-associated PAH. The size of the diamond indicates the degree of linkage disequilibrium with the strongest association (HLA-DQA1*03:02).


Disclosures: J. Qian, None; Y. Chen, None; X. Yang, None; Q. Wang, None; J. ZHAO, None; X. Deng, None; S. Li, None; Y. Liu, None; Z. Tian, None; J. Shen, None; Q. Liao, None; Y. Wang, None; X. Zuo, None; X. Zhang, None; M. LI, None; Y. Cui, None; X. Yu, None; X. Zeng, None.

To cite this abstract in AMA style:

Qian J, Chen Y, Yang X, Wang Q, ZHAO J, Deng X, Li S, Liu Y, Tian Z, Shen J, Liao Q, Wang Y, Zuo X, Zhang X, LI M, Cui Y, Yu X, Zeng X. Association Study Identified HLA-DQA1 as a Genetic Risk of Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/association-study-identified-hla-dqa1-as-a-genetic-risk-of-systemic-lupus-erythematosus-associated-pulmonary-arterial-hypertension/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-study-identified-hla-dqa1-as-a-genetic-risk-of-systemic-lupus-erythematosus-associated-pulmonary-arterial-hypertension/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology